ATE274350T1 - Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien - Google Patents

Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien

Info

Publication number
ATE274350T1
ATE274350T1 AT97905068T AT97905068T ATE274350T1 AT E274350 T1 ATE274350 T1 AT E274350T1 AT 97905068 T AT97905068 T AT 97905068T AT 97905068 T AT97905068 T AT 97905068T AT E274350 T1 ATE274350 T1 AT E274350T1
Authority
AT
Austria
Prior art keywords
adjuvants
peptides
pharmaceutical composition
modulation based
immune modulation
Prior art date
Application number
AT97905068T
Other languages
German (de)
English (en)
Inventor
Walter Schmidt
Max Birnstiel
Peter Steinlein
Michael Buschle
Tamas Schweighoffer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27215945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE274350(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Priority claimed from DE19638313A external-priority patent/DE19638313C2/de
Priority claimed from DE19648687A external-priority patent/DE19648687A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE274350T1 publication Critical patent/ATE274350T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97905068T 1996-02-24 1997-02-21 Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien ATE274350T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19638313A DE19638313C2 (de) 1996-09-19 1996-09-19 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687A DE19648687A1 (de) 1996-11-25 1996-11-25 Pharmazeutische Zusammensetzung für die Immunmodulation
PCT/EP1997/000828 WO1997030721A1 (de) 1996-02-24 1997-02-21 Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien

Publications (1)

Publication Number Publication Date
ATE274350T1 true ATE274350T1 (de) 2004-09-15

Family

ID=27215945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905068T ATE274350T1 (de) 1996-02-24 1997-02-21 Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien

Country Status (34)

Country Link
US (1) US7105162B1 (enExample)
EP (1) EP0881906B2 (enExample)
JP (1) JP4184433B2 (enExample)
KR (1) KR100457647B1 (enExample)
CN (1) CN1177610C (enExample)
AR (1) AR005945A1 (enExample)
AT (1) ATE274350T1 (enExample)
AU (1) AU722264B2 (enExample)
BG (1) BG63682B1 (enExample)
BR (1) BR9707694A (enExample)
CA (1) CA2243559C (enExample)
CO (1) CO4600681A1 (enExample)
CZ (1) CZ295396B6 (enExample)
DE (1) DE59711873D1 (enExample)
DK (1) DK0881906T4 (enExample)
EE (1) EE04481B1 (enExample)
ES (1) ES2225951T5 (enExample)
HR (1) HRP970100B1 (enExample)
HU (1) HU224410B1 (enExample)
ID (1) ID16038A (enExample)
IL (1) IL125361A (enExample)
MY (1) MY119276A (enExample)
NO (1) NO983850L (enExample)
NZ (1) NZ332020A (enExample)
PE (1) PE55398A1 (enExample)
PL (1) PL189413B1 (enExample)
PT (1) PT881906E (enExample)
RO (1) RO119344B1 (enExample)
RS (1) RS50101B (enExample)
SI (1) SI0881906T2 (enExample)
SK (1) SK284582B6 (enExample)
TR (1) TR199801649T2 (enExample)
TW (1) TW585774B (enExample)
WO (1) WO1997030721A1 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
DE69910743T2 (de) * 1998-02-25 2004-07-08 The Government Of The United States, As Represented By The Secretary Of The Army Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp-ribosylating-exotoxin induzierten immunantwort
DE69837350T2 (de) * 1998-04-20 2007-11-29 Torrey Pines Institute For Molecular Studies, San Diego Topische immunostimulierung zur induzierung der migration der langerhanszellen
EP1150710B1 (en) * 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
DE19909503A1 (de) * 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT409762B (de) * 2000-04-13 2002-11-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung von zytokin sekretierenden zellen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
KR20020014459A (ko) * 2000-08-18 2002-02-25 서진호 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법
EP1347776A2 (en) * 2001-01-05 2003-10-01 Intercell Biomedizinische Forschungs- und Entwicklungs AG Anti-inflammatory use of polycationic compounds
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
EP1347775B1 (en) * 2001-01-05 2016-11-30 Valneva Austria GmbH Uses for polycationic compounds as vaccine adjuvants
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
AU2002358616A1 (en) * 2001-12-07 2003-06-17 Intercell Ag Immunostimulatory oligodeoxynucleotides
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US7528223B2 (en) 2002-07-24 2009-05-05 Intercell Ag Antigens encoded by alternative reading frames from pathogenic viruses
JP2006504687A (ja) 2002-09-13 2006-02-09 インターツェル・アクチェンゲゼルシャフト Ｃ型肝炎ウイルスペプチドの単離方法
AU2003274011B2 (en) 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
PL1601770T3 (pl) 2003-03-04 2010-02-26 Intercell Ag Antygeny Streptococcus pyogenes
CA2517673C (en) 2003-03-24 2013-08-13 Intercell Ag Improved vaccines for preventing viral infection
DE602004024179D1 (de) 2003-03-31 2009-12-31 Intercell Ag Staphylococcus epidermidis antigene
EP2311988A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
CN101864431A (zh) 2003-05-07 2010-10-20 英特塞尔股份公司 无乳链球菌抗原ⅰ和ⅱ
EP1629005A2 (en) 2003-05-30 2006-03-01 Intercell AG Enterococcus antigens
JP4734241B2 (ja) 2003-07-11 2011-07-27 インターツェル・アクチェンゲゼルシャフト Ｈｃｖワクチン
EP1722819B1 (en) 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ES2344739T3 (es) 2004-09-24 2010-09-06 Intercell Ag Proteina capsidial vp1 modificada del parvovirus b19.
CA2583026A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients
WO2006112477A1 (ja) * 2005-04-20 2006-10-26 Taiho Pharmaceutical Co., Ltd. アジュバントとしてのポリアミノ酸
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
US8129165B2 (en) 2006-09-15 2012-03-06 Intercell Ag Borrelia antigens
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
CA2685805A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
KR100748265B1 (ko) * 2007-06-15 2007-08-10 (주)성문엔지니어링 공동주택에 배선된 전선의 합선방지구조
AU2008265218A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
PT2173376E (pt) 2007-08-02 2015-07-30 Biondvax Pharmaceuticals Ltd Vacinas de influenza multiepitópicas multiméricas
RU2494737C2 (ru) * 2008-03-27 2013-10-10 Нестек С.А. Способы увеличения абсорбции пептидов, пептидомиметиков и других субстратов гастроинтестинального транспортного белка
AU2009323682A1 (en) 2008-12-03 2010-06-10 Protea Vaccine Technologies Ltd. Glutamyl tRNA synthetase (GtS) fragments
US8617574B2 (en) 2009-02-13 2013-12-31 Valneva Austria Gmbh Nontypable Haemophilus influenzae antigens
BR112012004276A2 (pt) * 2009-08-27 2017-10-24 Novartis Ag adjuvante compreendendo alumínio, oligonucleotídeo e policátion
US9700650B2 (en) 2009-11-09 2017-07-11 Spotlight Technology Partners Llc Polysaccharide based hydrogels
NZ599527A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Fragmented hydrogels
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
RU2478399C2 (ru) * 2011-06-16 2013-04-10 Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) Способ получения специфического иммуномодулятора
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
CA3116265A1 (en) 2014-10-07 2016-04-14 Cytlimic Inc. Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
CN107847572A (zh) 2015-05-13 2018-03-27 艾吉纳斯公司 用于癌症治疗和预防的疫苗
EP3392291B1 (en) * 2015-12-16 2020-08-05 Huvet Bio, Inc. Vaccine adjuvant composition based on amphiphilic polyamino acid polymer, containing squalene
US12065699B2 (en) 2016-03-15 2024-08-20 Repertoire Genesis Incorporation Monitoring and diagnosis for immunotherapy, and design for therapeutic agent
US20200282032A1 (en) * 2016-05-27 2020-09-10 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
JP6998880B2 (ja) * 2016-10-11 2022-02-10 サイトリミック株式会社 医薬
CN107469067B (zh) * 2017-09-05 2018-06-19 浙江大学 一种多肽及其改造体在制备免疫调节药物中的应用
CN112218883A (zh) 2018-04-26 2021-01-12 艾吉纳斯公司 热休克蛋白结合肽组合物及其使用方法
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CN110870912A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用
CN117860879A (zh) * 2024-01-10 2024-04-12 广州医科大学附属肿瘤医院 一种纳米疫苗递送系统及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (enExample) 1968-05-31 1972-09-20
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4728639A (en) * 1982-07-27 1988-03-01 University Of Tennessee Research Corporation Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
BE1000587A4 (fr) 1986-06-13 1989-02-14 Oncogen Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.
DE68925660T2 (de) * 1988-06-10 1996-09-26 United Biomedical Inc Peptidfragmente von HIV
JP2955314B2 (ja) * 1988-10-27 1999-10-04 リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ Ｉｌ―２含有リポソーム免疫アジュバント
CA2072351A1 (en) 1990-01-05 1991-07-06 Andrew J. Mcmichael Hiv-1 core protein fragments
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
DE69333434T2 (de) 1992-04-03 2005-03-03 The Regents Of The University Of California, Oakland Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US5571711A (en) 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
CZ3000U1 (cs) 1993-07-12 1995-02-22 Kufudakis Alekos Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
UY24367A1 (es) 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju

Also Published As

Publication number Publication date
HRP970100B1 (en) 2001-04-30
YU6297A (sh) 1999-09-27
AR005945A1 (es) 1999-07-21
NZ332020A (en) 2000-02-28
PL189413B1 (pl) 2005-08-31
PT881906E (pt) 2004-10-29
RO119344B1 (ro) 2004-08-30
TW585774B (en) 2004-05-01
CA2243559A1 (en) 1997-08-28
BG102714A (en) 1999-06-30
EE9800255A (et) 1999-02-15
ES2225951T3 (es) 2005-03-16
EE04481B1 (et) 2005-06-15
HK1017257A1 (en) 1999-11-19
CO4600681A1 (es) 1998-05-08
RS50101B (sr) 2009-01-22
MY119276A (en) 2005-04-30
BR9707694A (pt) 1999-07-27
DE59711873D1 (de) 2004-09-30
US7105162B1 (en) 2006-09-12
SI0881906T1 (en) 2004-12-31
BG63682B1 (bg) 2002-09-30
IL125361A0 (en) 1999-03-12
JP2000506125A (ja) 2000-05-23
EP0881906A1 (de) 1998-12-09
ID16038A (id) 1997-08-28
EP0881906B1 (de) 2004-08-25
HUP9901186A2 (hu) 1999-07-28
ES2225951T5 (es) 2009-06-15
SK114598A3 (en) 1999-06-11
KR19990082601A (ko) 1999-11-25
SI0881906T2 (sl) 2009-06-30
TR199801649T2 (xx) 1998-12-21
JP4184433B2 (ja) 2008-11-19
DK0881906T3 (da) 2004-12-20
CZ295396B6 (cs) 2005-08-17
PE55398A1 (es) 1998-09-22
NO983850D0 (no) 1998-08-21
SK284582B6 (sk) 2005-07-01
HUP9901186A3 (en) 2001-01-29
WO1997030721A1 (de) 1997-08-28
NO983850L (no) 1998-10-21
HU224410B1 (hu) 2005-08-29
CA2243559C (en) 2011-08-09
CZ268998A3 (cs) 1999-07-14
PL328455A1 (en) 1999-02-01
KR100457647B1 (ko) 2005-06-20
CN1177610C (zh) 2004-12-01
AU722264B2 (en) 2000-07-27
CN1211926A (zh) 1999-03-24
DK0881906T4 (da) 2009-05-25
EP0881906B2 (de) 2009-02-04
AU1875997A (en) 1997-09-10
HRP970100A2 (en) 1998-04-30
IL125361A (en) 2002-08-14

Similar Documents

Publication Publication Date Title
ATE274350T1 (de) Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien
DE69526801D1 (de) Aerosolformulierungen mit peptiden und proteinen
BR9607317A (pt) Peptídios e composição farmacêutica
BR9607318A (pt) Peptidos e composição farmacêutica
HUP9904177A3 (en) Antibody against human parathormone related peptides
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
EP0950665A4 (en) PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
FI962554L (fi) Potilaan hoitolaite sekä hoitojärjestelmä
DE69733994D1 (de) Sauger zur medikamentenverabreichung
HUP9902751A3 (en) Oral peptide pharmaceutical products
AU4172597A (en) Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
FI954978L (fi) Modifioidut proteiini- ja peptidilääkeaineet
IL114407A0 (en) Novel peptides and pharmaceutical compositions comprising them
FI963196L (fi) Melanoomaspesifisten sytoksisten lymfosyyttien tunnistamia peptidejä ja niiden käyttö
ZA978383B (en) Pharmaceutical compositions comprising amisulpride and therapeutic applications thereof.
EP0923605A4 (en) Conjugated vaccines containing mucin
NO990836D0 (no) Antitrombotiske azacykloalkylalkanoylpeptider og pseudopeptider
ITMI942663A0 (it) Proteine ricche in idrossiprolina e formulazioni farmaceutiche e cosmetiche che le compongono
IL112075A0 (en) Recombinant human thymopoietin proteins, their preparation and their medicinal use
EE9800275A (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
EP0970965A4 (en) CYCLIC PEPTIDES AND MEDICAL USE THEREOF
DE69816241D1 (de) Aktivierte peptide und konjugate
KR960010685A (ko) 펩티드 및 그 용도
ZA976547B (en) Lipid-binding proteins and their therapeutic and diagnostic use
DE59406425D1 (de) Abtrenneinheit und saugeinheit für dentale zwecke